Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | PRKDC | P78527 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.36 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.36 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2956149 | 0.84 | CSF1R (0.39) | CSF1RMAPTPOLBMAPK1CHRNA7 | |
| SCHEMBL2950397 | 0.84 | BRD4 (0.38) | RAB9ASMN1; SMN2KDM4ECSF1RMAPT | |
| SCHEMBL2956387 | 0.81 | MAPT (0.43) | RAB9ASMN1; SMN2KDM4ECSF1RMAPT | |
| SCHEMBL2958644 | 0.81 | RAB9A (0.39) | RAB9ASMN1; SMN2KDM4ECSF1RMAPT | |
| SCHEMBL2949261 | 0.81 | IDO1 (0.39) | RAB9ASMN1; SMN2MAPTPIK3CAPRKDC | |
| SCHEMBL2949616 | 0.78 | DRD4 (0.40) | RAB9ASMN1; SMN2KDM4ECSF1RMAPT | |
| SCHEMBL6102447 | 0.78 | CSF1R (0.35) | CSF1RPOLBGAAMAPK1CHRNA7 | |
| SCHEMBL2949780 | 0.78 | MAPT (0.47) | RAB9ASMN1; SMN2KDM4ECSF1RMAPT | |
| SCHEMBL2952347 | 0.76 | IDO1 (0.40) | RAB9ASMN1; SMN2KDM4ECSF1RMAPT | |
| SCHEMBL2949768 | 0.74 | MAPT (0.41) | RAB9ASMN1; SMN2KDM4EMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423047-B2 | Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors | CELLTECH R&D LIMITED (GB) | 2008-09-09 | — | — | US | claimed |
| US-20060004025-A1 | Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors | UCB PHARMA S.A. (BE) | 2006-01-05 | — | — | US | claimed |
| US-7763729-B2 | Bicyclic heteroaromatic derivatives | UCB PHARMA S.A. (BE) | 2010-07-27 | — | — | US | disclosed |
| US-20090042877-A1 | Bicyclic Heteroaromatic Derivatives | CELLTECH R&D LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| US-7482452-B2 | Process for preparing 3-aminothienopyridone derivatives | CELLTECH R&D LIMITED (GB) | 2009-01-27 | — | — | US | disclosed |
| EP-1638980-B1 | PROCESS FOR PREPARING 3-AMINOTHIENOPYRIDONE DERIVATIVES | UCB PHARMA SA (BE) | 2008-11-05 | — | — | EP | disclosed |
| US-7423047-B2 | Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors | CELLTECH R&D LIMITED (GB) | 2008-09-09 | — | — | US | disclosed |
| US-20070191608-A1 | Process for preparing 3-aminothienopyridone derivatives | CELLTECH R&D LIMITED (GB) | 2007-08-16 | — | — | US | disclosed |
| US-20060004025-A1 | Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors | UCB PHARMA S.A. (BE) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191608-A1 | Process for preparing 3-aminothienopyridone derivatives | MAPK3, MAP3K6, MAP4K1 | RAB9A 1925/4885SMN1; SMN2 3748/4885KDM4E 1879/4885 |
| US-20060004025-A1 | Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors | MAPK1, CNKSR1, ALK | RAB9A 3150/4885SMN1; SMN2 3637/4885KDM4E 2174/4885 |
| US-20090042877-A1 | Bicyclic Heteroaromatic Derivatives | MAPK1, CNKSR1, CBR1 | RAB9A 2791/4885SMN1; SMN2 3472/4885KDM4E 2211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.